Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Larazotide Acetate to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Pediatric and Adult Participants With Well-Controlled Celiac Disease
The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Larazotide acetate is being studied as a preventative therapy in individuals with well-controlled celiac disease. The primary objective of the study is to evaluate the protective effects of larazotide acetate compared to placebo on histologic changes and patient-reported outcomes following simulated inadvertent gluten exposure.
A total of 414 patients will be randomized 1:1:1 to receive either 0.25 mg larazotide acetate, 0.5 mg larazotide acetate, or placebo. All three study arms will take the assigned treatment as an oral capsule three times daily (TID). The treatment period will be 14 weeks, with an up to 8-week screening period and a 4-week follow-up period. During parts of the study, participants will also eat daily food bars that may contain a small amount of gluten, to simulate inadvertent gluten exposure in the real world. The doses of larazotide acetate being evaluated in this study were selected as the most promising doses to maximize efficacy based on previous clinical data.
Efficacy will be assessed via patient-reported outcomes, including but not limited to a daily and two weekly patient questionnaires, and histological changes, as evaluated via endoscopies with duodenal biopsy at screening/baseline and at the end of the treatment period. Safety will be assessed via adverse event reporting, laboratory evaluations, vital sign evaluations, and physical examinations at regular intervals.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Jay Madan
- Numer telefonu: 919-995-4130
- E-mail: info@interludebio.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Participant is male or female ≥ 12 and ≤ 80 years of age.
- Participant has a body mass index (BMI) between 16 and 45 kg/m2, inclusive.
- Participant has biopsy-proven CeD confirmed by medical records.
- Participant has IgA anti-tissue transglutaminase (tTG) antibodies ≤1.5 times the upper limit of normal during screening.
- Participant is willing to undergo all assessments in the protocol, including two esophagogastroduodenoscopies with duodenal biopsies (i.e., baseline and Week 14).
- Participant has followed a gluten-free diet (GFD) for at least 12 consecutive months immediately prior to screening and is willing to maintain this diet for the duration of the study.
- Participant is willing and able to refrain from taking prohibited medications during the study.
- If taking medications for chronic use, the subject has been on a stable dose for ≥ 4 weeks prior to screening and has no plans to change during the study.
- Participant is capable of understanding the requirements of the study, is willing to comply with all study procedures, understands the language of the informed consent/assent form, and is capable and willing to sign the informed consent/assent form.
- Participant has a Weekly CDSD GI symptom severity score ≤ 0.400 AND participant has no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), AND no individual GI symptom scores of severe or greater severity (a score of ≥3) for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score during the symptom eligibility screening period (Visit 2). Note: Participants must meet symptom criteria to undergo baseline EGD.
- Participant has a Vh:Cd ratio ≥2.5 at the time of baseline endoscopy (i.e., within 14 days prior to randomization).
Exclusion Criteria:
-
Participant is diagnosed with inflammatory or other clinically significant GI disease or systemic autoimmune disease other than CeD that either has the potential to cause persistent GI symptoms similar to CeD or is not well controlled without the use of excluded medication, including but not limited to: Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), eosinophilic esophagitis, gastroparesis, colitis, Type 1 diabetes, autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus.
-
Participant has a history of dermatitis herpetiformis.
-
Participant has known or suspected type 2 refractory CeD or ulcerative jejunitis.
-
Participant has selective IgA deficiency.
-
Participant has a diagnosis of small intestinal bacterial overgrowth within 3 months prior to screening.
-
Participant has ongoing pancreatic insufficiency.
-
Participant has a known hypersensitivity reaction and/or allergy, including anaphylaxis, to the study drug or any of its components, wheat and/or gluten, or any other ingredients in SIGE bar.
-
Participant had major GI surgery within the last six months prior to screening.
-
Ongoing systemic immunosuppressant treatment, systemic corticosteroid treatment, or treatment with immunosuppressant or corticosteroids in the 12 weeks before screening.
-
Participant has received oral, intramuscular (IM), or intravenous (IV) antibiotics within four weeks prior to screening.
-
Participant has ongoing chronic use (defined as >7 days continuous use) of a nonsteroidal anti-inflammatory drug (aside from ≤100 mg aspirin, daily, for prophylactic use).
-
Participant has ongoing use, or use in the 3 months before screening, of medications known to cause villous abnormalities (such as, but not limited to: mycophenolate mofetil, angiotensin receptor blockers, colchicine).
-
Participant has used treatments for GI signs and/or symptoms, including antiemetics, antidiarrheals, antispasmodics, and medical marijuana (use of medical marijuana indicated for non-GI conditions is not exclusionary) within 2 weeks prior to and during the Screening period. Participants on a stable dose (i.e., more than 4 weeks) of an osmotic, bulking-forming, or emollient (surface active agent) laxative are eligible, provided symptoms are considered not related to CeD in the investigator's opinion.
-
Participant initiated treatment with a GLP-1 receptor agonist or GLP-1-containing combination therapy or experienced a dose change in their GLP-1 receptor agonist or GLP-1-containing combination therapy regimen within 12 weeks prior to Screening. Participants receiving a stable dose for at least 12 weeks prior to Screening are eligible.
-
Participant has received an investigational product within 30 days prior to screening, or the subject intends to participate in another clinical study while participating in this study.
-
Participant has received treatment for alcohol or drug abuse in the past year.
-
Participant has a known history of human immunodeficiency virus (HIV), hepatitis B or C infection.
-
Participant has a diagnosis of cancer occurring within five years prior to study entry. NOTE: Participant diagnosed with non-melanoma skin cancer, cervical carcinoma-in-situ, or early-stage prostate cancer that has been treated successfully with curative therapy at least one year prior to study entry, as demonstrated by medical records, is exempt from this exclusion criteria.
-
Participant has any co-morbid disease or clinically significant abnormal laboratory test results that would make the subject unsuitable for enrollment, as determined by the Principal Investigator or qualified designee and confirmed by the study Medical Monitor.
-
Participant is pregnant or lactating.
-
Participant has childbearing potential and is unwilling to use an acceptable method of birth control for the duration of the study. Acceptable methods of birth control include:
- Use of double barrier methods (e.g., diaphragm, cervical cap, or condom [male or female] and spermicidal gel, foam, sponges, or film)
- Use of an intrauterine device (IUD)
- Hormonal contraception (e.g., oral, patch, vaginal ring, implanted or injectable hormonal contraceptive)
- Surgical sterilization (vasectomy for men or bilateral oophorectomy, hysterectomy, or tubal ligation for women)
- Post-menopausal (12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy)
- To be a monogamous partner of a sterile male is an acceptable method of birth control. Abstinence is acceptable as long as female participants agree to use contraception if and when they are sexually active.
-
Noncompliance with baseline diary entries (>3 missing diary entries from Symptom Eligibility Period).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Larazotide Acetate 0.25 mg
Oral administration of 0.25 mg larazotide acetate capsules, TID, for 14 weeks. |
Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks. |
|
Eksperymentalny: Larazotide Acetate 0.5 mg
Oral administration of 0.5 mg larazotide acetate capsules, TID, for 14 weeks. |
Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks. |
|
Komparator placebo: Placebo
Oral administration of placebo capsules, TID, for 14 weeks. |
Placebo capsules will be taken orally TID for 14 weeks. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of responders treatment with larazotide acetate (0.25 mg or 0.5 mg) compared to placebo during the last two weeks of the 14-week treatment period
Ramy czasowe: Last two weeks of the treatment period (Weeks 13-14)
|
Responders are defined as participants who continue to meet the baseline criteria for well-controlled CeD, based on both symptom and histologic parameters, as outlined below:
|
Last two weeks of the treatment period (Weeks 13-14)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of participants with a Vh:Cd ratio ≥2.5 at the end of the 14-week treatment period.
Ramy czasowe: End of treatment (Week 14)
|
Vh:Cd ratio will be determined based on the Week 14 endoscopy with duodenal biopsy. Higher Vh:Cd ratios indicate a lesser extent of damage. |
End of treatment (Week 14)
|
|
Proportion of participants with a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent moderate score and no severe score, for core GI symptoms, during the last two weeks of the 14-week treatment period
Ramy czasowe: Last two weeks of the treatment period (Weeks 13-14)
|
The Weekly CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the past 7 days. Higher scores indicate worse symptom severity. No persistent moderate score = no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days) No severe score = no individual GI symptom scores of severe or greater severity (a score of ≥3) Core GI symptoms of CeD = abdominal pain, bloating, diarrhea, and nausea, as measured by the CDSD v2.1 symptom severity score during the last two weeks of the 14-week treatment period. |
Last two weeks of the treatment period (Weeks 13-14)
|
|
Mean change from baseline in Vh:Cd ratio at the end of the 14-week treatment period
Ramy czasowe: Baseline and End of treatment (Week 14)
|
Vh:Cd ratios will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher Vh:Cd ratio indicates a lesser extent of damage. |
Baseline and End of treatment (Week 14)
|
|
Change from baseline in intraepithelial lymphocyte (IEL) density at the end of the 14-week treatment period
Ramy czasowe: Baseline and End of treatment (Week 14)
|
IEL density will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher IEL density indicates increased disease activity. |
Baseline and End of treatment (Week 14)
|
|
Proportion of weeks maintaining well-controlled disease-related symptoms during the 14-week treatment period
Ramy czasowe: Entire treatment period (14 weeks)
|
Well-controlled disease-related symptoms is defined as a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), and no individual GI symptom scores of severe or greater severity (a score of ≥3), for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score. |
Entire treatment period (14 weeks)
|
|
Proportion of symptom-free days, defined as no core GI symptoms of CeD for a 24-hour period
Ramy czasowe: Entire treatment period (14 weeks)
|
A symptom-free day is when all four core GI symptom scores (abdominal pain, bloating, diarrhea, nausea) are 0 during a 24-hour period, as measured by the CDSD v2.1 symptom severity score. |
Entire treatment period (14 weeks)
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Ramy czasowe |
|---|---|
|
Incidence and severity of treatment-emergent adverse events
Ramy czasowe: First treatment through end of follow-up (~Week 18)
|
First treatment through end of follow-up (~Week 18)
|
|
Incidence of treatment-related adverse events
Ramy czasowe: First treatment through end of follow-up (~Week 18)
|
First treatment through end of follow-up (~Week 18)
|
|
Incidence of serious adverse events
Ramy czasowe: First treatment through end of follow-up (~Week 18)
|
First treatment through end of follow-up (~Week 18)
|
|
Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation of study medication
Ramy czasowe: First treatment through end of treatment (Week 14)
|
First treatment through end of treatment (Week 14)
|
|
Change from baseline in systolic blood pressure
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in diastolic blood pressure
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in heart rate
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in respiratory rate
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in oral temperature
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in weight
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
|
Change from baseline in Body Mass Index
Ramy czasowe: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CeD-LA-3002
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .